1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018, 68(6):394–424.
2.Claiborne PM, Fowler CS, Vaporciyan AA: Follow-up of patients with resected thoracic malignancies. Thoracic surgery clinics 2012, 22(1):123–131, viii.
3.Travis WD, Rekhtman N: Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Seminars in respiratory and critical care medicine 2011, 32(1):22–31.
4.Zhang YL, Zhang ZL, Zhu XB, Xu L, Lu P, Xu M, Liu WJ, Zhang XY, Yao HM, Ye XW: Low plasma miR–25 expression is a favorite prognosis factor in non-small cell lung cancer. European review for medical and pharmacological sciences 2019, 23(12):5251–5259.
5.Mazzone PJ, Sears CR, Arenberg DA, Gaga M, Gould MK, Massion PP, Nair VS, Powell CA, Silvestri GA, Vachani A et al: Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement. American journal of respiratory and critical care medicine 2017, 196(7):e15-e29.
6.Aguiar PN, Jr., De Mello RA, Hall P, Tadokoro H, Lima Lopes G: PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy 2017, 9(6):499–506.
7.Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, Nakanishi Y: Diagnostic value of CEA and CYFRA 21–1 tumor markers in primary lung cancer. Lung Cancer 2013, 80(1):45–49.
8.Marenholz I, Heizmann CW, Fritz G: S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochemical & Biophysical Research Communications 2004, 322(4):1111–1122.
9.Schafer BW, Wicki R, Engelkamp D, Mattei MG, Heizmann CW: Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family. Genomics 1995, 25(3):638–643.
10.Nacken W, Roth J, Sorg C, Kerkhoff C: S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech 2003, 60(6):569–580.
11.Donato R: Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003, 60(6):540–551.
12.Wang T, Huo X, Chong Z, Khan H, Liu R, Wang T: A review of S100 protein family in lung cancer. Clinica chimica acta; international journal of clinical chemistry 2018, 476:54–59.
13.Lukanidin E, Sleeman JP: Building the niche: the role of the S100 proteins in metastatic growth. Seminars in cancer biology 2012, 22(3):216–225.
14.Mishra SK, Siddique HR, Saleem M: S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence. Cancer and Metastasis Reviews 2012, 31(1):163–172.
15.Lee SW, Tomasetto C, Swisshelm K, Keyomarsi K, Sager R: Down-Regulation of a Member of the S100 Gene Family in Mammary Carcinoma Cells and Reexpression by Azadeoxycytidine Treatment. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(6):2504.
16.Liu YF, Liu QQ, Wang X, Luo CH: Clinical significance of S100A2 expression in gastric cancer. Tumor Biology 2014, 35(4):3731–3741.
17.Feng G, Xu X, Youssef EM, Lotan R: Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. Cancer Res 2001, 61(21):7999–8004.
18.Wang T, Liang Y, Thakur A, Zhang S, Liu F, Khan H, Shi P, Wang N, Chen M, Ren H: Expression and clinicopathological significance of S100 calcium binding protein A2 in lung cancer patients of Chinese Han ethnicity. Clinica chimica acta; international journal of clinical chemistry 2017, 464:118–122.
19.Wang T, Liang Y, Thakur A, Zhang S, Yang T, Chen T, Gao L, Chen M, Ren H: Diagnostic significance of S100A2 and S100A6 levels in sera of patients with non-small cell lung cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 2016, 37(2):2299–2304.
20.Chen H, Xu C, Jin Q, Liu Z: S100 protein family in human cancer. American journal of cancer research 2014, 4(2):89–115.
21.Suzuki F, Oridate N, Homma A, Nakamaru Y, Nagahashi T, Yagi K, Yamaguchi S, Furuta Y, Fukuda S: S100A2 expression as a predictive marker for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral cavity. Oncology Reports 2005, 14(6):1493–1498.
22.Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R: Expression of calcium-binding protein S100A2 in breast lesions. Br J Cancer 2000, 83(11):1473–1479.
23.Maelandsmo GM, Florenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O: Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. International journal of cancer 1997, 74(4):464–469.
24.Luo J, Zhu Y, Yang G, Gong L, Wang B, Liu H: Loss of Reprimo and S100A2 expression in human gastric adenocarcinoma. Diagnostic cytopathology 2011, 39(10):752–757.
25.Sato Y, Harada K, Sasaki M, Nakanuma Y: Clinicopathological significance of S100 protein expression in cholangiocarcinoma. Journal of gastroenterology and hepatology 2013, 28(8):1422–1429.
26.Feng G, Xu X, Youssef EM, Lotan R: Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. Cancer Research 2001, 61(21):7999–8004.
27.Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC, Ratschiller D, Gugger M, Donovan M, Lasek A et al: Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 2002, 21(50):7749–7763.
28.Hsieh HL, Schafer BW, Sasaki N, Heizmann CW: Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochemical and biophysical research communications 2003, 307(2):375–381.
29.Diederichs S, Bulk E, Steffen B, Ji P, Tickenbrock L, Lang K, Zanker KS, Metzger R, Schneider PM, Gerke V et al: S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res 2004, 64(16):5564–5569.
30.Smith SL, Gugger M, Hoban P, Ratschiller D, Watson SG, Field JK, Betticher DC, Heighway J: S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas. Br J Cancer 2004, 91(8):1515–1524.
31.Naz S, Bashir M, Ranganathan P, Bodapati P, Santosh V, Kondaiah P: Protumorigenic actions of S100A2 involve regulation of PI3/Akt signaling and functional interaction with Smad3. Carcinogenesis 2014, 35(1):14–23.
32.Bulk E, Sargin B, Krug U, Hascher A, Jun Y, Knop M, Kerkhoff C, Gerke V, Liersch R, Mesters RM et al: S100A2 induces metastasis in non-small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 2009, 15(1):22–29.